Patent application number | Description | Published |
20090037900 | METHOD FOR OPTIMIZING MEMORY MODULES FOR USER-SPECIFIC ENVIRONMENTS - A method for altering and preferably optimizing the performance of system memory of a computer system. The method includes identifying the motherboard and the memory module of the computer system, and then searching multiple SPD update files associated with multiple motherboards and containing data corresponding to physical and operational characteristics of multiple memory modules. From these SPD update files, a compatible SPD update file is identified that is compatible with the motherboard and contains data corresponding to physical and operational characteristics of the memory module. Thereafter, a software utility is used to erase pre-existing SPD data stored on the SPD circuit device and then write and verify installation of the data of the compatible SPD update file on the SPD circuit device. New SPD settings for the memory module are then enabled based on the data of the compatible SPD update file. | 02-05-2009 |
20110053429 | CONNECTOR ASSEMBLY AND METHOD FOR SATA DRIVES - A connector assembly and method suitable for making data and power connections with mass storage devices that use the SATA interface standard. The connector assembly includes a connector having a pair of oppositely-disposed surfaces, a face between the surfaces, and data and power connector portions disposed in the face. The data and power connector portions are adapted to establish data and power connections between the connector and a SATA interface of a mass storage device. The connector assembly further has data and power cables for transmitting, respectively, data and power through the data and power connector portions of the connector. Opposing clips protrude from the oppositely-disposed surfaces of the connector and project beyond the face of the connector. The clips engage opposing sides of the mass storage device and mechanically stabilize the data and power connections between the connector and the SATA interface of the mass storage device. | 03-03-2011 |
20110138113 | RAID STORAGE SYSTEMS HAVING ARRAYS OF SOLID-STATE DRIVES AND METHODS OF OPERATION - RAID storage systems and methods adapted to enable the use of NAND flash-based solid-state drives. The RAID storage system includes an array of solid-state drives and a controller operating to combine the solid-state drives into a logical unit. The controller utilizes data striping to form data stripe sets comprising data (stripe) blocks that are written to individual drives of the array, utilizes distributed parity to write parity data of the data stripe sets to individual drives of the array, and writes the data blocks and the parity data to different individual drives of the array. The RAID storage system detects the number of data blocks of at least one of the data stripe sets and then, depending on the number of data blocks detected, may invert bit values of the parity data or add a dummy data value of “1” to the parity value. | 06-09-2011 |
20120173795 | SOLID STATE DRIVE WITH LOW WRITE AMPLIFICATION - A solid state drive having a non-volatile memory device and methods of operating the solid state drive to compare existing data stored on the memory device to subsequent data in an incoming data stream received by the solid state drive from a host system. If matching data are found, the solid state drive uses the existing data instead of writing the subsequent data to the memory device. Common data patterns can be shared among different files stored on the memory device. | 07-05-2012 |
20150039971 | RAID STORAGE SYSTEMS HAVING ARRAYS OF SOLID-STATE DRIVES AND METHODS OF OPERATION - RAID storage systems and methods adapted to enable the use of NAND flash-based solid-state drives. The RAID storage system includes an array of solid-state drives and a controller operating to combine the solid-state drives into a logical unit. The controller utilizes data striping to form data stripe sets comprising data (stripe) blocks that are written to individual drives of the array, utilizes distributed parity to write parity data of the data stripe sets to individual drives of the array, and writes the data blocks and the parity data to different individual drives of the array. The RAID storage system detects the number of data blocks of at least one of the data stripe sets and then, depending on the number of data blocks detected, may invert bit values of the parity data or add a dummy data value of “1” to the parity value. | 02-05-2015 |
Patent application number | Description | Published |
20100206727 | TEST STRIP COMPRISING PATTERNED ELECTRODES - Described herein is an analyte test strip and method for making the test strip. The test strip utilizes isolated conductive areas to define electrode whiskers. The method utilizes laser ablation to define electrode patterns. | 08-19-2010 |
20110005941 | METHODS FOR DETERMINING AN ANALYTE CONCENTRATION USING SIGNAL PROCESSING ALGORITHMS - A method for determining an analyte concentration in blood is described that reduces the effects of hematocrit using a test strip attached to a test meter. The test strip includes a working electrode and a reference electrode. The test meter applies a test voltage between the working electrode and the reference electrode. After a user applies a blood sample containing an analyte onto the test strip, the test meter measures a plurality of test currents for a test time interval. | 01-13-2011 |
20110048972 | MULTI-ANALYTE TEST STRIP WITH SHARED COUNTER/REFERENCE ELECTRODE AND INLINE ELECTRODE CONFIGURATION - A multi-analyte test strip includes a first insulating layer and an electrically conductive layer disposed on the first insulating layer. The electrically conductive layer has a first working electrode with a first analyte contact pad, a shared counter/reference electrode with a counter/reference electrode contact pad, and a second working electrode with a second analyte contact pad. The multi-analyte test strip also includes a second insulating layer disposed above the first insulating layer and a patterned spacer layer positioned between the first insulating layer and the first electrically conductive layer with the patterned spacer layer defining a bodily fluid sample-receiving chamber that overlies the first working electrode, the shared counter/reference electrode and the second working electrode. The multi-analyte test strip further includes a mediator reagent layer disposed over the first working electrode, the shared counter/reference electrode and the second working electrode; a first analyte reagent layer disposed over the first working electrode and mediator reagent layer; and a second analyte reagent layer disposed over the second working electrode and mediator reagent layer. Furthermore, the first analyte electrode, shared counter/reference electrode and second analyte electrode of the multi-analyte test strip are disposed on the first insulating layer in a planar inline configuration. | 03-03-2011 |
20110094882 | TEST METER FOR USE WITH A DUAL CHAMBER, MULTI-ANALYTE TEST STRIP WITH OPPOSING ELECTRODES - A test meter for use with a dual-chamber, multi-analyte test strip includes a test strip receiving module and a signal processing module. The test strip receiving module has a first electrical connector configured for contacting a first analyte contact pad of a first working electrode of the test strip; a second electrical connector configured for contacting a second analyte contact pad of a second working electrode of the test strip, a third electrical connector configured for contacting a first counter/reference contact pad of a first counter/reference electrode layer of the test strip, and a fourth electrical connector configured for contacting a second counter/reference contact pad of a second counter/reference electrode layer of the test strip. The signal processing module is configured to receive a first signal via the first electrical connector and the third electrical connector and employ the first signal for the determination of a first analyte (such as glucose) in a bodily fluid sample (for example, whole blood sample) applied to the dual-chamber, multi-analyte test strip. Moreover, the signal processing module is also configured to receive a second signal via the second electrical connector and fourth electrical connector and employ the second signal for the determination of a second analyte (e.g., a ketone analyte) in the bodily fluid sample applied to the dual-chamber, multi-analyte test strip. Furthermore, the third and fourth electrical contacts provide contact in an opposing manner. | 04-28-2011 |
20110094896 | DUAL CHAMBER, MULTI-ANALYTE TEST STRIP WITH OPPOSING ELECTRODES - A dual chamber, multi-analyte test strip has a first insulating layer, a first electrically conductive layer, with a first working electrode, disposed on the first insulating layer and a first patterned spacer layer positioned above the first electrically conductive layer. The first patterned spacer layer has a first sample-receiving chamber, with first and second end openings, defined therein that overlies the first working electrode. The test strip also includes a first counter/reference electrode layer that is exposed to the first sample receiving chamber and is in an opposing relationship to the first working electrode. The test strip further includes a counter/reference insulating layer disposed over the first counter/reference electrode layer and a second counter/reference electrode layer disposed on the counter/reference substrate. Also included in the test strip is a second patterned spacer layer that is positioned above the second counter/reference electrode layer. The second patterned spacer layer has a second sample-receiving chamber, with first and second end openings, defined therein. The test strip additionally has a second electrically conductive layer, with a second working electrode, disposed above the second patterned spacer layer, a second insulating layer disposed above the second electrically conductive layer, a first analyte reagent layer disposed on the first working electrode within the first sample-receiving chamber; and a second analyte reagent layer disposed on the second working electrode within the second sample-receiving chamber. The second counter/reference electrode layer is exposed to the second sample receiving chamber and is in an opposing relationship to the second working electrode. | 04-28-2011 |
20110162978 | SYSTEMS AND METHODS FOR DETERMINING A SUBSTANTIALLY HEMATOCRIT INDEPENDENT ANALYTE CONCENTRATION - A method and system is provided to allow for determination of substantially Hematocrit independent analyte concentration. In one example, an analyte measurement system is provided that includes a test strip and a test meter. The test strip includes a reference electrode and a working electrode, in which the working electrode is coated with a reagent layer. The test meter includes an electronic circuit and a signal processor. The electronic circuit applies a plurality of voltages to the reference electrode and the working electrode over respective durations. The signal processor is configured to determine a substantially hematocrit-independent concentration of the analyte from a plurality of current values as measured by the processor upon application of a plurality of test voltages to the reference and working electrodes over a plurality of durations interspersed with rest voltages lower than the test voltages being applied to the electrodes. | 07-07-2011 |
20120199497 | ELECTROCHEMICAL-BASED ANALYTICAL TEST STRIP WITH DIFFUSION-CONTROLLING LAYER AND METHOD FOR DETERMINING AN ANALYTE USING SUCH AN TEST STRIP - An electrochemical-based analytical test strip for the determination of an analyte (such as glucose) in a bodily fluid sample (e.g., a whole blood sample) includes a substrate, at least one working electrode disposed on the substrate, a sample-soluble enzymatic reagent layer disposed above the working electrode, a diffusion-controlling layer (DCL) disposed between the at least one working electrode and the sample-soluble enzymatic reagent layer; and a sample-receiving chamber. In addition, the sample-soluble enzymatic reagent layer is configured and constituted for operable solubility in a bodily fluid sample applied to the electrochemical-based analytical test strip and received in the sample-receiving chamber and for electrochemical enzymatic reaction with an analyte in the bodily fluid sample. Moreover, the DCL is configured and constituted to provide a predetermined diffusion rate for a component (for example a mediator) of the electrochemical enzymatic reaction through the DCL that is less than the diffusion rate of the component through the bodily fluid sample and for operable hydration by the bodily fluid sample. A method for determining an analyte in a bodily fluid sample includes applying a bodily fluid sample to an electrochemical-based analytical test strip that includes a substrate, at least one working electrode disposed on the substrate, a sample-soluble enzymatic reagent layer disposed above the working electrode, a DCL disposed between the at least one working electrode and the sample-soluble enzymatic reagent layer; and a sample-receiving chamber defined in the electrochemical-based analytical test strip. | 08-09-2012 |
20130037421 | SYSTEMS AND METHODS FOR DETERMINING A SUBSTANTIALLY HEMATOCRIT INDEPENDENT ANALYTE CONCENTRATION - A method and system is provided to allow for determination of substantially Hematocrit independent analyte concentration. In one example, an analyte measurement system is provided that includes a test strip and a test meter. The test strip includes a reference electrode and a working electrode, in which the working electrode is coated with a reagent layer. The test meter includes an electronic circuit and a signal processor. The electronic circuit applies a plurality of voltages to the reference electrode and the working electrode over respective durations. The signal processor is configured to determine a substantially hematocrit-independent concentration of the analyte from a plurality of current values as measured by the processor upon application of a plurality of test voltages to the reference and working electrodes over a plurality of durations interspersed with rest voltages lower than the test voltages being applied to the electrodes. | 02-14-2013 |
20130240375 | METHOD FOR DETERMINING HEMATOCRIT CORRECTED ANALYTE CONCENTRATIONS - The method includes: providing a test strip comprising a reference electrode and a working electrode coated with a reagent layer; applying a fluid sample to the test strip for a reaction period; applying a test voltage between the reference electrode and the working electrode; measuring a test current as a function of time; measuring a steady state current value when the test current has reached an equilibrium; calculating a ratio of the test current to the steady state current value; plotting the ratio of the test current to the steady state current value as a function of the inverse square root of time; calculating an effective diffusion coefficient from the slope of the linearly regressed plot of the ratio of the test current to the steady state current value as a function of the inverse square root of time; and calculating a hematocrit-corrected concentration of analyte. | 09-19-2013 |
20150068920 | FILL SUFFICIENCY METHOD AND SYSTEM - Described and illustrated herein are one exemplary method and a measurement system having a meter and a test strip. The test strip has a first working electrode, reference electrode and second working electrode. In this method, acceptable fill data from known first current and known second current are used to predict an estimated second current at proximate the second time period (for a given batch of test strips) during the test sequence. The estimated second current at proximate the second time interval is then compared with a measured actual second current at proximate the second time interval during an actual test to determine if the measured actual second current is substantially equal to or within an acceptable percent deviation from the estimated second current so as to determine sufficient volume of a physiological fluid sample in the test strip. | 03-12-2015 |
Patent application number | Description | Published |
20080212694 | Signal decoding systems - We describe a method of decoding a DCM (dual carrier modulation) modulated OFDM signal, the method comprising: inputting first received signal data representing modulation of a multibit data symbol onto a first carrier of said OFDM signal using a first constellation; inputting second received signal data representing modulation of said multibit data symbol onto a second, different carrier of said OFDM signal using a second, different constellation; determining a combined representation of said first and second received signal data, said combined representation representing a combination of a distance of a point representing a bit value of said multibit data from a constellation point in each of said different constellations; and determining a decoded value of a data bit of said multibit data using said combined representation. | 09-04-2008 |
20140140448 | Reduced-Complexity Maximum Likelihood MIMO Receiver - A method of performing maximum likelihood detection on spatially-multiplexed streams in a multiple-input multiple-output (MIMO) communication system, the method comprising: receiving plurality of received signals at a plurality of receiver antennas, the plurality of received signals corresponding to a plurality of transmit symbols, each transmit symbol being one of a number M possible symbols, for each of a value k=1 to M: select a first stream candidate symbol, for each receiver antenna, calculate a residual signal, combine said calculated residual signals, select a second stream candidate symbol for said value k based on the result of said combination to form a symbol pair comprising said first stream candidate symbol and said second stream candidate symbol; and calculate a corresponding distance metric for said symbol pair for said value k, selecting one of the symbol pairs based on said calculated distance metrics. | 05-22-2014 |
20140334561 | Method and System for Symbol Detection Using Matrix Decomposition - This application proposes using successive interference cancellation with an ordered matrix decomposition coupled with a search based ordered layer detection technique. The search based ordered layer detection technique is used to consider a plurality of hypothesis decision estimates for detection of symbols in multiple data streams. | 11-13-2014 |
20150063503 | Maximum Likelihood Detection - A method of symbol detection in an electronic device employing multi-user multiple input multiple output (MU-MIMO) communication over a first transmission layer of first and second transmission layers comprises various steps. A receiver comprises processing circuitry for performing these steps. A transmitted signal is received. The transmitted signal is decoded by detecting data symbols within the transmitted signal for the first transmission layer by performing Maximum Likelihood (ML) detection on the first transmission layer. ML detection comprises performing a search across all possible symbol constellation points in a set of constellation points available for the second transmission layer. | 03-05-2015 |
Patent application number | Description | Published |
20120135992 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS - The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula (I): in which z is a single bond or an optionally substituted linking group, R1 is a halo-alkyl group; and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system; or a salt thereof. | 05-31-2012 |
20120135993 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS - The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The triazine compounds are of formula (I) wherein: R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when R1 is hydrogen or ═NH when R1 is a substituent group; R3 and R4 are both carbocyclic, heterocyclic or alkyl groups and may be same or different; and R5 is hydrogen, alkyl or a cyclic aryl group, with the proviso that: when R3 and R4 are both alkyl they are linked to form a cycloalkyl group, and R5 is a cyclic aromatic group; and when R3 and R4 are both carbocyclic or heterocyclic groups, R5 is hydrogen or an alkyl group; or a salt thereof. | 05-31-2012 |
20140243343 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS - The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula I: | 08-28-2014 |
Patent application number | Description | Published |
20090291954 | Medical Use of Triazine Derivatives - Compounds of formula (I) especially where R | 11-26-2009 |
20110009413 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS - Compounds of general structure in which X and Y are each N or C with at least one of X and Y being N; Z is a single bond or an optionally substituted linking group R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when RI is hydrogen or ═NH when R1 is a substituent group; or N* is a group NRaRb where Ra and Rb are independently H or an alkyl group; or N* is an optionally substituted piperazinyl ring; and A is an optionally substituted heterocyclic or carbocyclic ring system which may be linked to the triazo/diazo ring through R2 to form a fused multicyclic ring; are indicated as suitable for treatment of disorders in mammals that are susceptible to sodium channel blockers and antifolates, and particularly disorders such epilepsy, multiple sclerosis, glaucoma and uevitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motorneurone disease, Alzheimer's disease, Parkinson's disease, chronic inflammatory pain, neuropathic pain, migraine, bipolar disorder, mood, anxiety and cognitive disorders, schizophrenia and trigeminal autonomic cephalalgias; for treatment of mammalian cancers; and for treatment of malaria. | 01-13-2011 |
20130005732 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES - Compounds of formula (I): | 01-03-2013 |
Patent application number | Description | Published |
20090036410 | Structured Phospholipids - A method of treating a patient in need of therapy for a disease in which cyokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, is provided comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterifed with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of γ-linolenoyl, dihomo-γ-linolenoyl acid and arachidonoyl. | 02-05-2009 |
20100113595 | Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 05-06-2010 |
20100113810 | Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 05-06-2010 |
20120142775 | TREATMENT OF NEURODEGENERATIVE CONDITIONS - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 06-07-2012 |
Patent application number | Description | Published |
20090023807 | Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a monoglyceride or metabolic precursor thereof of general formula (I), wherein R | 01-22-2009 |
20090137660 | Cytokine Modulators Using Cyclic Glycerides of Essential Polyunsaturated Fatty Acids - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R | 05-28-2009 |
20100297196 | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R | 11-25-2010 |
20110184063 | Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both γ-linolenic acid and linoleic acid residues as triglyceride ester, the ratio of γ-linolenic acid to linoleic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of γ-linolenic acid residues at the sn-2 position being at least 18%, wherein the oil is administered at a dose sufficient to maintain or elevate TGF-β1 levels in the patient at a therapeutic level. Preferably the method is that wherein the therapeutic level is such as to produce a TGF-β1/TNF-α ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing. Preferred oils are Borage or Mucor oils having at least 35% of the sn-2 position fatty acid residues as γ-linolenic acid. | 07-28-2011 |